183 related articles for article (PubMed ID: 27110669)
1. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.
Cong X; Cremer C; Nachreiner T; Barth S; Carloni P
Protein Sci; 2016 Aug; 25(8):1451-60. PubMed ID: 27110669
[TBL] [Abstract][Full Text] [Related]
2. Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.
Cremer C; Braun H; Mladenov R; Schenke L; Cong X; Jost E; Brümmendorf TH; Fischer R; Carloni P; Barth S; Nachreiner T
Cancer Immunol Immunother; 2015 Dec; 64(12):1575-86. PubMed ID: 26472728
[TBL] [Abstract][Full Text] [Related]
3. Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.
Cremer C; Vierbuchen T; Hein L; Fischer R; Barth S; Nachreiner T
J Immunother; 2015 Apr; 38(3):85-95. PubMed ID: 25710248
[TBL] [Abstract][Full Text] [Related]
4. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM
Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226
[TBL] [Abstract][Full Text] [Related]
5. Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival.
Pizzo E; Sarcinelli C; Sheng J; Fusco S; Formiggini F; Netti P; Yu W; D'Alessio G; Hu GF
J Cell Sci; 2013 Sep; 126(Pt 18):4308-19. PubMed ID: 23843625
[TBL] [Abstract][Full Text] [Related]
6. Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.
Bochicchio A; Jordaan S; Losasso V; Chetty S; Perera RC; Ippoliti E; Barth S; Carloni P
Biomedicines; 2017 Feb; 5(1):. PubMed ID: 28536352
[TBL] [Abstract][Full Text] [Related]
7. Angiogenin (ANG)-Ribonuclease Inhibitor (RNH1) System in Protein Synthesis and Disease.
Sarangdhar MA; Allam R
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525475
[TBL] [Abstract][Full Text] [Related]
8. Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.
Nassiri M; Ghovvati S; Gharouni M; Tahmoorespur M; Bahrami AR; Dehghani H
Protein J; 2024 Apr; 43(2):316-332. PubMed ID: 38145445
[TBL] [Abstract][Full Text] [Related]
9. Human angiogenin is a potent cytotoxin in the absence of ribonuclease inhibitor.
Thomas SP; Hoang TT; Ressler VT; Raines RT
RNA; 2018 Aug; 24(8):1018-1027. PubMed ID: 29748193
[TBL] [Abstract][Full Text] [Related]
10. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
11. Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41.
Holloway DE; Chavali GB; Hares MC; Baker MD; Subbarao GV; Shapiro R; Acharya KR
Biochemistry; 2004 Feb; 43(5):1230-41. PubMed ID: 14756559
[TBL] [Abstract][Full Text] [Related]
12. Ribonuclease inhibitor regulates neovascularization by human angiogenin.
Dickson KA; Kang DK; Kwon YS; Kim JC; Leland PA; Kim BM; Chang SI; Raines RT
Biochemistry; 2009 May; 48(18):3804-6. PubMed ID: 19354288
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
Shapiro R; Ruiz-Gutierrez M; Chen CZ
J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748
[TBL] [Abstract][Full Text] [Related]
14. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
15. Selective abolition of pancreatic RNase binding to its inhibitor protein.
Kumar K; Brady M; Shapiro R
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):53-8. PubMed ID: 14681553
[TBL] [Abstract][Full Text] [Related]
16. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
Chen CZ; Shapiro R
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of murine angiogenin-2 and -3-probing 'structure--function' relationships amongst angiogenin homologues.
Iyer S; Holloway DE; Acharya KR
FEBS J; 2013 Jan; 280(1):302-18. PubMed ID: 23170778
[TBL] [Abstract][Full Text] [Related]
18. Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations.
Padhi AK; Jayaram B; Gomes J
Sci Rep; 2013; 3():1225. PubMed ID: 23393617
[TBL] [Abstract][Full Text] [Related]
19. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.
Stöcker M; Tur MK; Sasse S; Krüssmann A; Barth S; Engert A
Protein Expr Purif; 2003 Apr; 28(2):211-9. PubMed ID: 12699683
[TBL] [Abstract][Full Text] [Related]
20. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
